Non-Specific Interstitial Pneumonia in a Woman with Osteoporosis Treated with Denosumab

Denosumab is an antiresorptive monoclonal antibody widely used in the treatment of osteoporosis. A rare and potentially life-threatening adverse reaction likely associated with denosumab treatment is described, presenting as the first case report in the English literature of non-specific interstitial pneumonia (NSIP), to the best of our knowledge. The importance of clinically recognising drug-induced manifestations is evidenced in this case, where early withdrawal of the drug is usually associated with a clinical-prognostic improvement.